Advertisement
Dainippon Sumitomo Pharma
Subscribe to Dainippon Sumitomo Pharma

The Lead

Dainippon Sumitomo Pharma to Stop Trial on New Colon Cancer Drug

May 23, 2014 7:55 am | News | Comments

Dainippon Sumitomo Pharma Co. said today it will effectively stop a clinical trial on a new colon cancer treatment drug it had hoped to start selling in the United States during the year from next April.        

Edison Pharmaceuticals and Dainippon Sumitomo Pharma Form Strategic Alliance

January 31, 2014 8:59 am | News | Comments

Edison Pharmaceuticals today announced that it has entered into a strategic alliance valued up...

Dainippon Sumitomo Pharma to Establish Anti-Cancer Drugs Sales Company in U.S.

October 9, 2013 9:00 am | News | Comments

Dainippon Sumitomo Pharma Co., Ltd. (DSP) has decided to establish an anti-cancer drugs sales...

Dainippon Sumitomo Pharma to Acquire Boston Biomedical

February 29, 2012 3:09 am | News | Comments

Dainippon Sumitomo Pharma Co. said today it has agreed to acquire Boston Biomedical Inc., known...

View Sample

FREE Email Newsletter

Silence Therapeutics and Dainippon Sumitomo Expand siRNA Delivery Collaboration

March 30, 2010 4:43 am | News | Comments

Silence Therapeutics plc today announced that the company and Dainippon Sumitomo Pharma Co., Ltd. have agreed to an expansion of their ongoing small interfering RNA (siRNA) delivery collaboration.

Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia

March 11, 2010 3:35 am | News | Comments

Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia.

Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia

January 5, 2010 4:19 am | News | Comments

Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia.

Dainippon of Japan Acquires Sepracor for $2.6 billion

September 3, 2009 4:30 am | News | Comments

TOKYO (AP) — Japanese drug company Dainippon Sumitomo Pharma Co. is acquiring U.S. drug maker Sepracor Inc. for about $2.6 billion in an effort to expand in the U.S. market, both sides said Thursday.

Advertisement
X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading